trial · primary record
Pembrolizumab
High-risk Non-muscle Invasive Bladder Cancer
| Phase | Phase 3 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 1397 |
| Primary completion | 2034-11-20 |
| Primary endpoint | Complete Response Rate (CRR) by Blinded Independent Central Review (BICR) (Cohort A) |
| Registry ID | NCT03711032 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:32:36.334Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT03711032
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.